Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown‐Frandsen, HM Colhoun… - …, 2023 - Wiley Online Library
Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

[HTML][HTML] Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

DH Ryan, I Lingvay, HM Colhoun, J Deanfield… - American heart …, 2020 - Elsevier
Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has
been widely appreciated that obesity is a major risk factor for CVD, treatments that produce …

[HTML][HTML] Semaglutide and cardiovascular outcomes in obesity without diabetes

AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic …

DK McGuire, RP Busui, J Deanfield… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL)
and the baseline clinical data of its participants. Materials and methods In SOUL, the effects …

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

M Husain, SC Bain, AG Holst, T Mark… - Cardiovascular …, 2020 - Springer
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

DH Ryan, I Lingvay, J Deanfield, SE Kahn, E Barros… - Nature medicine, 2024 - nature.com
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

Semaglutide in patients with obesity-related heart failure and type 2 diabetes

MN Kosiborod, MC Petrie, BA Borlaug… - … England Journal of …, 2024 - Mass Medical Soc
Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

SP Marso, SC Bain, A Consoli… - … England Journal of …, 2016 - Mass Medical Soc
Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …